CRDF Cardiff Oncology Inc

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT -

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29 after the close of trading.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 29, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at . A replay will be available in the investor relations section on the company's website following the completion of the call.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit

Cardiff Oncology Contact:

James Levine

Chief Financial Officer

858-952-7670

Investor Contact:

Kiki Patel, PharmD

Gilmartin Group

332-895-3225

Media Contact:

Richa Kumari

Taft Communications

551-344-5592



EN
22/02/2024

Underlying

CRDFCardiff Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cardiff Oncology Inc

 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology to Present at Upcoming Investor Conferences in May SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024. Details of the presentations can be found below. H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQLocation: The Nasdaq Headquarters, New York CityPresenter: Mark Erlander, CEOFormat: Fireside ChatDate:...

May 13, 2024 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Reports First Quarter 2024 Results and Provides Busin...

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update - In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib’s antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvansertib’s acti...

May 2, 2024 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology to Report First Quarter 2024 Results and Provide Busi...

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update - Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading. Conference Call and Webcast ...

April 25, 2024 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meetin...

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onva...

April 8, 2024 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual M...

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced publications of five abstracts that will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10, 2024, in San Diego, California. “The posters we will be presenting at this year’s AACR meeting represent a broad v...

March 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch